scholarly journals Acquired von Willebrand disease in chronic myeloproliferative disorders: a prospective single-center study

2019 ◽  
pp. 123-127
Author(s):  
Ömer Ekinci ◽  
Muhammed Aslanboğa
Keyword(s):  
Myeloproliferative Disorders ◽  
Von Willebrand Disease ◽  
Single Center ◽  
Chronic Myeloproliferative Disorders ◽  
Acquired Von Willebrand Disease ◽  
Single Center Study ◽  
Von Willebrand ◽  
Center Study

Acquired von Willebrand Disease in Myeloproliferative Disorders

1996 ◽  
Vol 22 (sup1) ◽  
pp. 79-82 ◽  
Author(s):  
Perry J. J. Van Genderen ◽  
Henriette Leenknegt ◽  
Jan J. Michiels ◽  
Ulrich Budde
Keyword(s):  
Myeloproliferative Disorders ◽  
Von Willebrand Disease ◽  
Acquired Von Willebrand Disease ◽  
Von Willebrand

scholarly journals A Case of Acquired von Willebrand Disease Secondary to Myeloproliferative Neoplasm

2020 ◽  
Vol 13 (2) ◽  
pp. 733-737 ◽  
Author(s):  
Sreethish Sasi ◽  
Mohamed A. Yassin ◽  
Afraa M. Fadul
Keyword(s):  
Early Recognition ◽  
Myeloproliferative Neoplasm ◽  
Myeloproliferative Disorders ◽  
Acute Onset ◽  
Von Willebrand Disease ◽  
Acquired Von Willebrand Disease ◽  
History Of ◽  
Underlying Disorder ◽  
Von Willebrand ◽  
Willebrand Factor

Acquired von Willebrand Disease (AVWD) is a rare disorder in which qualitative or quantitative defects in von Willebrand factor (VWF) occur secondary to other conditions. AVWD occurs in patients with myeloproliferative disorders due to formation of autoantibodies against VWF and development of excessive shear stress causing disruption of VWF multimers. AVWD is different from congenital VWD in its acute onset and absence of family history. We report a 42-year-old gentleman with essential thrombocythemia, who was on cytoreductive therapy with hydroxyurea, and presented with an acute history of gum bleeding with hemoptysis, without any antecedent trauma or infections. His platelet count was very high, and prothrombin time and activated partial thromboplastin time were prolonged. The VWF ristocetin cofactor assay (VWF: RCo) was low, but VWF antigen level (VWF: Ag) was normal. Their ratio (VWF: RCo/VWF: Ag) was much lower than the acceptable lower limit. Treatment in AVWD is focused on addressing the underlying disorder. Early recognition of AVWD and its primary cause is mandatory in providing adequate therapy and achieving a cure.

1655: Long-Term Functional Outcome in Orthotopic Bladder Replacement in Women: A Single Center Study

2007 ◽  
Vol 177 (4S) ◽  
pp. 549-549
Author(s):  
Hannes Steiner ◽  
Thomas Akkad ◽  
Christian Gozzi ◽  
Brigitte Springer-Stoehr ◽  
Georg Bartsch
Keyword(s):  
Functional Outcome ◽  
Single Center ◽  
Bladder Replacement ◽  
Single Center Study ◽  
Center Study

ENDOSCOPIC TREATMENT OF RECTAL NEUROENDOCRINE TUMORS IN A 12 YEAR RETROSPECTIVE SINGLE CENTER STUDY

2019 ◽  
Author(s):  
K Dąbkowski ◽  
A Białek ◽  
N Rusiniak-Rossińska ◽  
K Michalska ◽  
B Kos-Kudła ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Endoscopic Treatment ◽  
Single Center ◽  
Single Center Study ◽  
Center Study
Sign in / Sign up

Export Citation Format

Share Document